Alphatec vs Bioventus
ATEC and BVS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATEC and BVS compare
Alphatec is the larger company, worth 1.2 times as much as Bioventus ($1.1B against $924M).
Alphatec grew revenue faster over the last twelve months (15.3% versus 3.9% for Bioventus).
Bioventus keeps more of each dollar of sales as profit, with a net margin of 9.8% compared with −10.3% at Alphatec.
Bioventus scores higher on the StockData Score (14 against 7 for Alphatec), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATEC | BVS |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $924M |
| Share price | $7.35 | $10.99 |
| Change, 1 year | −63.7% | 46.7% |
| Change, 5 years | −34.8% | −21.6% |
| Beta (5Y) | 1.17 | 0.91 |
| Employees | 913 | 930 |
| StockData Score | ||
| Total score | 7 | 14 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 3 | 3 |
| Performance score | 2 | 5 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 13.7× |
| P/S | 1.4× (better) | 1.6× |
| P/B | – | 3.8× |
| EV/EBITDA | 41.2× | 14.4× (better) |
| P/FCF | 372× | 10.9× (better) |
| FCF yield | 0.27% | 9.2% (better) |
| Fair value | – | $16.36 |
| Margin of safety | – | 32.8% |
| Growth | ||
| Revenue growth (TTM) | 15.3% (better) | 3.9% |
| Revenue growth, 5Y average | 39.5% (better) | 12.1% |
| Net income growth (TTM) | – | 655% |
| EPS growth (TTM) | – | 627% |
| Profitability | ||
| Gross margin | 71.3% (better) | 68.7% |
| Operating margin | −3.6% | 9.7% (better) |
| Net margin | −10.3% | 9.8% (better) |
| FCF margin | 0.37% | 14.5% (better) |
| Return on equity | −1888% | 28.2% (better) |
| Return on invested capital | −5.0% | 12.8% (better) |
| Financial health | ||
| Debt / equity | – | 0.96 |
| Net debt / EBITDA | 12.06 | 2.44 (better) |
| Interest coverage | −0.7× | – |
| Current ratio | 2.36 (better) | 1.68 |
| Altman Z-score | −0.46 | 2.19 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.31% |
| Shareholder yield | 0.00% (better) | −0.31% |
| Ownership | ||
| Held by institutions | 72.7% | 71.2% |
| Held by insiders | 23.5% | 29.0% |
| Insider net buying, 12 months | −$40.9M | −$181K (better) |
| Short interest, % of float | 12.0% | 5.1% |
Go deeper
- ATEC stock overview
- ATEC income statement
- ATEC valuation and score
- BVS stock overview
- BVS income statement
- BVS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.